Kulika Weizman
General Partner at Creative Ventures
San Francisco Bay Area
Overview
Work Experience
General Partner
2023 - Current
Invest in early-stage deep tech companies, solving humanity’s most critical crises—rising healthcare costs, climate change, and labor shortages.
Principal
2021 - 2023
Senior Associate
2018 - 2020
Board Member
2023
Board Observer
2023
Tierra Biosciences is a synthetic biology company that offers an AI-driven platform with a vast range of custom proteins for research.
Raised $36,608,498.00 from Freeflow Ventures, Creative Ventures, Prosus Ventures, Material Impact, IQT, Social Capital, Hillspire and Creative Ventures.
Board Observer
2022
Board Observer
2022
Synvivia creates organisms that can be controlled with small molecules.
Raised $375,910.00 from California Innovation Fund and Creative Ventures.
Board Observer
2021
Rhaeos is a medical device company that develops wearable sensors to improve the treatment of chronic health conditions.
Raised $19,640,256.00 from National Institutes of Health and Consortium For Technology & Innovation in Pediatrics.
Board Observer
2023
Board Member
2021 - 2023
VenoStent is a tissue engineering medical device company developing bioabsorbable polymer wraps for better outcomes in vascular surgery.
Raised $29,818,706.00 from Good Growth Capital, Norwest Venture Partners, IAG Capital Partners, Creative Ventures, SNR.vc, TMC Venture Fund, IAG Capital Partners, Alumni Ventures and Baylor Angel Network.
Board Observer
2021
Unique Treatments for Unique Patients
Raised $4,160,000.00 from AIR Capital, IndieBio and SOSV.
Investor
2020
Cytonus is a biotech company combining AI-driven drug discovery together with a class defining drug-delivery platform called the Cargocyte
Raised $20,943,095.00 from Creative Ventures, Wilson Sonsini Goodrich & Rosati, Prox Ventures, Gemseki, Partners Investment, John Ballantyne and KreaMedica.
Investor
2020